Forbion Capital Partners

Forbion Capital Partners

Forbion Capital Partners

Forbion Capital Partners invests in Life Sciences and Biomedical Technology companies developing worldclass drugs and technologies, with a clear focus on product development..
Type
B2b
Founded
2007
Follow us
$450,000,000
FinSMEs

Bayer to Buy KaNDy Therapeutics

$115,000,000 Venture capital
FinSMEs

Dyne Therapeutics Raises $115M in Equity Financing

$62,500,000 Venture capital (Series A)
FinSMEs

Prilenia Therapeutics Raises $62.5M in Series A Funding

€25,000,000 Venture capital (Series A)
FinSMEs

Azafaros Closes €25M Series A Financing

$40,000,000 Venture capital (Series B)
FinSMEs

NorthSea Therapeutics Raises US $40M in Series B Financing

PE HUB

Hookipa Pharma debuts IPO

$37,400,000 Venture capital (Series D)
FinSMEs

Hookipa Pharma Raises $37.4M in Series D Financing

MedCity News

bluebird bio's stock tanks after report of serious toxicity in sickle cell patient

$80,000,000 Venture capital
FinSMEs

Milestone Pharmaceuticals Raises $80M in Equity Funding

Funding Health
£25,000,000 Venture capital (Series C)
FinSMEs , MedCity News , PE HUB

KaNDy Therapeutics Raises £25M in Series C Financing

Health Funding
FinSMEs

Lundbeck to Acquire Prexton Therapeutics, for €905M

Health Science
$59,600,000 Venture capital (Series C)
PE HUB

| Hookipa Biotech scores $59.6 mln Series C

PE HUB

Merck to buy VC-backed Rigontec

Health Funding
$30,000,000 Venture capital (Series C)
citybizlist

citybizlist : Exosome Diagnostics Raises $30M Series C

€17,500,000 Post-IPO equity
morningstar , Labiotech.eu

Cellnovo Successfully Raises €17.5 Million from Healthcare Investors

$250,000,000 Post-IPO equity
Twitter

Boston Business on Twitter

$18,400,000 Venture capital (Series A)
stevenagecatalyst , biospace

Stevenage BioScience Catalyst | The Stevenage Voice - February 2013 |

£23,000,000 Venture capital (Series B)
PE Hub , GEN , pharmatimes

NeRRE Therapeutics picks up Series B funds

€5,400,000 Venture capital
cellnovo

Press Releases | The Cellnovo Diabetes Management System

Stock markets
rigontec

Rigontec GmbH – A Dual Approach To Treat Cancer is a privately held biopharmaceutical company that develops RNA-based im...

Health Science Funding